SCHEMBL7573006

SCHEMBL7573006

COc1ccc(CNc2cccnc2)c(-c2cccc(C3(C)NC(=N)N(CC4CCN(C(C)=O)CC4)C3=O)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.39
PDE4B Q07343 1/20 0.37
MARK3 P27448 1/20 0.36
GRIN2B Q13224 1/20 0.36
DGAT2 Q96PD7 3/20 0.36
BACE1 P56817 2/20 0.36
CTSD P07339 1/20 0.36
CTSE P14091 1/20 0.36
BRD4 O60885 1/20 0.36
EP300 Q09472 1/20 0.36
CREBBP Q92793 1/20 0.36
CCR3 P51677 1/20 0.35
ITGA4 P13612 1/20 0.35
ITGB7 P26010 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
FAAH O00519 1/20 0.34
ACP1 P24666 1/20 0.34
KIT P10721 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2969070 0.93 ACP1 (0.39) PIK3CGDGAT2BACE1CCR3RXFP1
SCHEMBL7567782 0.90 PIK3CG (0.38) PIK3CGBACE1CTSDCTSECCR3
SCHEMBL7568587 0.88 L3MBTL1 (0.40) PIK3CGDGAT2BACE1RXFP1
SCHEMBL7566199 0.87 BACE1 (0.40) PIK3CGDGAT2BACE1CTSDRXFP1
SCHEMBL7581366 0.87 BACE1 (0.40) PIK3CGBACE1CTSDRXFP1ACP1
SCHEMBL8207880 0.87 RXFP1 (0.38) PIK3CGDGAT2BACE1CTSDRXFP1
SCHEMBL7599920 0.86 FASN (0.39) PIK3CGBACE1EP300RXFP1ACP1
SCHEMBL7568353 0.85 RXFP1 (0.39) PIK3CGBACE1CCR3RXFP1ACP1
SCHEMBL7546227 0.85 BACE1 (0.39) PIK3CGBACE1CTSDCTSERXFP1
SCHEMBL7563541 0.85 PDCD1LG2 (0.40) PIK3CGBACE1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829036-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-11-01 US disclosed
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-11-01 US disclosed
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-09-13 US disclosed
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PHARMACOPEIA INC. (US) 2012-09-13 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 PIK3CG 4102/4885PDE4B 3792/4885MARK3 2236/4885
US-20120276118-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS BACE1, PRSS1, TMPRSS11D PIK3CG 3319/4885PDE4B 1899/4885MARK3 1348/4885
US-20120231017-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS BACE1, PRSS1, TMPRSS11D PIK3CG 3319/4885PDE4B 1899/4885MARK3 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.